Микробиологические аспекты гнойно-воспалительных процессов при осложненных формах эхинококкоза

<4>Литература:
1. Perry, CM, Wagstaff, AJ. Famciclovir, A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections.//Drugs. 1995. -№ 50. -P. 396.
2. Perry, CM, Faulds, D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties, and therapeutic efficacy in herpesvirus infections.//Drugs. 1996. -Ns 52.- P. 754.
3. Benedetti, JK, Zeh, J, Corey, L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. //Ann Intern Med. 1999. -№ 131. -P. 14.
4. Фрейдлин И.С. Иммунная система и ее дефекты .//Руководство для врачей. СПб., 1998. -Р.113 ~° с.
5. Bryson, YJ, Dillon, M, Lovett, M, et ah Treatment of first episodes of genital herpes simplex virus infections with oral acyclovir.// N EnglJ Med. 1983. -№ 308. -P. 916.
6. Sexually Transmitted Diseases Treatment Guidelines, 20Q6J/ MMWR Recomm Rep. 2006 .(RR-11). -№ 551. -P. 95.
7. Crute, JJ, Grygon, CA, Hargrove, KD, et ah Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.// Nat Med. 2002.-№ 8. -P. 386.
8. Drugs for sexually transmitted infections.// Treat Guidel Med Lett. 2004. -№ 2.- P. 67.
9. Drugs for non-HIV viral infections.// Treat Guidel Med Lett. 2005. -№ 3. -P. 23.
10. Reichman, RC, Badger, GJ, Mertz, GJ, et ah Treatment of recurrent genital herpes simplex infections with oral acyclovir. //JAMA .1984. -№ 251. -P. 2103,
11. Wald, A, Carrett, D, Remington, M, et al. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection.// Clin Infect Dis. 2002. -№34.-P. 944.
12. Sacks, SL, Aoki, FY, Diaz-Motoma, F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: A randomized, double-blind multicenter trial. //JAMA .1996. -№ 276.-P.44.
13. Sacks, SL. Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial. //JInfect Dis .2004.-№ 189.-P.1341.
14. Aoki, FY, Tyring, S, Diaz-Mitoma, F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial.//Clin Infect Dis . 2006 -№42.-P. 8.
15. Bodsworth, NJ, Crooks, RJ, Borelli, S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: A randomised, double blind clinical trial./IGenitourin Med. 1997. -№ 73.-P. 110.
16. Gupta, R, Wald, A, Krantz, E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.//J Infect Dis. 2004. -№ 190.-P.1374.
17. Douglas, JM, Critchlow, C, Benedetti, J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. //N EnglJ Med. 1984. -№ 310. -P.1551.
JS Mertz GJ Manavemenr nfvenitai Ьр.гпрл /7 A/hi Krn Men Rmi jy96-J\iq 47
19. Mertz, GJ, Loveless, MO, Levin, MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: A multicenter, double-blind, placebo-controlled trial. //Arch Intern Med. 1997.-№ 157.-P. 343.
20. Corey, L, Wald, A, Patel, R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. //N EnglJ Med. 2OO4.-№ 350.-Р. 11.
21. Patel, R, Bodsworth, NJ, Woolley, P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: A placebo controlled study of once daily therapy: International Valaciclovir HSV Study Group. //Genitourin Med. 1997. -№ 73. -P.105.
22. Levin, MJ, Bacon, TH, Leary, JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infectedpatients.//Clin Infect Dis. 2004.-№ 39. Suppl 5.-P. 248.
23. Wade, JC, McLaren, C, Meyers, JD. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. //JInfect Dis. 1983.-№ 148.-P.1077.
24. Chibo, D, Mijch, A, Doherty, R, Birch, C. Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromisedpatient. l/JClin Virol. 2002.-№ 25.-P.165.
25. Reyes, M, Shaik, NS, Graber, JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics.//Arch Intern Med.2003.-№ 163.-P.76.
26. Danve-Szatanek, C, Aymard, M, Thouvenot, D, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. //J Clin Microbiol. 2004.-№ 42. -P. 242.
27. Erlich, KS, Mills, J, Charts, P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. /IN Engl JMed. 1989. -№ 320. —P. 293.
28. Safrin, S, Assaykeen, T, Follansbee, S, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: Preliminary data. I/' J Infect Dis. 199O.-№ 161.-P.1078.
29. Alvarez-McLeod, A, Havlik, J, Drew, KE. Foscarnet treatment of genital infection due to acyclovir-resistant herpes simplex virus type 2 in a pregnant patient with AIDS: case report.// Clin Infect Dis. 1999. -№ 29.-P. 937.
30. Ioannidis, JP, Collier, AC, Cooper, DA, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomised individual patient data.// J infect Dis. 1998. -№178. -P. 349.
31. Benson, CA, Kaplan, JE, Masur, H, et al. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. /I MMWR RecommRep. 2004. -№ 53.-P. 1.
32. Balfour, HHJr. Antiviral drugs. //NEnglJMed. 1999. -№ 340.-P. 1255.
33. Safrin, S, Elbeik, T, Phan, L, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients.// Antimicrob Agents Chemother. 1994. -№38. -P. 1246.